Eli Lilly reports positive results from study of thyroid cancer treatment
Eli Lilly & Co. (LLY) on Tuesday reported positive results from a study evaluating its targeted therapy Retevmo versus the current standard initial treatments for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer. Retevmo demonstrated a significant and clinically meaningful improvement in progression-free survival, compared with the multikinase inhibitors cabozantinib and vandetanib, Lilly said in a release. The data "suggest Retevmo should be considered the preferred first-line treatment" for people with this type of thyroid cancer, Dr. David Hyman, chief medical officer of Loxo@Lilly, said in a statement. Earlier this month, Lilly also reported that Retevmo demonstrated improved progression-free survival compared with platinum-based chemotherapy in patients with RET fusion-positive advanced or metastatic non-small cell lung cancer, intensifying competition with Blueprint Medicines Corp.'s (BPMC) RET inhibitor Gavreto. Lilly shares rose 0.1% premarket on Tuesday and have gained 50% in the year to date, while the S&P 500 is up 14.6%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-22-23 0833ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth
-
Palantir Earnings: AI Platform Drives Strong Start to 2024
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks